Catalog No.
DHC27703
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P07766
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MGA-031 / MGA031, PRV-031, CAS: 876387-05-2
Clone ID
Teplizumab
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes, PMID: 31180194
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial, PMID: 21719095
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders, PMID: 23835333
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis, PMID: 30569273
Antibodies to watch in 2020, PMID: 31847708
Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes, PMID: 28664195
Teplizumab for treatment of type 1 diabetes mellitus, PMID: 22968521
Teplizumab in Relatives at Risk for Type 1 Diabetes, PMID: 31693815
Teplizumab in Relatives at Risk for Type 1 Diabetes, PMID: 31693816
Teplizumab in Relatives at Risk for Type 1 Diabetes, PMID: 31693817
Teplizumab therapy for type 1 diabetes, PMID: 20095914
Teplizumab in Relatives at Risk for Type 1 Diabetes. Reply, PMID: 31693818
New Frontiers in the Treatment of Type 1 Diabetes, PMID: 31839487
Teplizumab delays onset of type 1 diabetes mellitus, PMID: 31243389
Safety and Efficacy of Teplizumab for Treatment of Type One Diabetes Mellitus: A Systematic Review and Meta-analysis, PMID: 33302842
Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups, PMID: 32960433
Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside, PMID: 27161438
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes, PMID: 32023396
Changing the landscape for type 1 diabetes: the first step to prevention, PMID: 31533907
Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development, PMID: 24517093
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals, PMID: 33658358
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial, PMID: 23086558
Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial, PMID: 23801579
Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients, PMID: 22277969
Teplizumab Improves Beta Cell Function, Delays Type 1 Diabetes, PMID: 33847731
Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes, PMID: 26518356
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years, PMID: 19443276
Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes, PMID: 32833543
Prospects for therapeutic tolerance in humans, PMID: 24378931
Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes, PMID: 32789003
Immunotherapies currently in development for the treatment of type 1 diabetes, PMID: 26364507
Immunotherapies in diabetes mellitus type 1, PMID: 22703858
Microbiota control immune regulation in humanized mice, PMID: 29093268
Anti-CD3 drug keeps diabetes at bay, PMID: 31578500
Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases, PMID: 23254986
Traveling down the Long Road to Type 1 Diabetes Mellitus Prevention, PMID: 31180193
Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D, PMID: 31157632
Anti-CD3 clinical trials in type 1 diabetes mellitus, PMID: 23726024
Anti-CD3 Antibody for the Prevention of Type 1 Diabetes: A Story of Perseverance, PMID: 31523950
Prevention versus intervention of type 1 diabetes, PMID: 23803322
Preclinical efficacy of humanized, non-FcγR-binding anti-CD3 antibodies in T-cell acute lymphoblastic leukemia, PMID: 32483610
Primary and secondary prevention of Type 1 diabetes, PMID: 23231526
Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes, PMID: 28844471
Immune therapy and β-cell death in type 1 diabetes, PMID: 23423576
Immunomodulators: Cell savers, PMID: 22616095
Solving the Puzzle of Immune Tolerance for β-Cell Replacement Therapy for Type 1 Diabetes, PMID: 33007232
Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease, PMID: 25437293
Anti-CD3 mAbs for treatment of type 1 diabetes, PMID: 19319985
Type 1 diabetes pathogenesis - Prevention???, PMID: 25941654
A future for CD3 antibodies in immunotherapy of type 1 diabetes, PMID: 30612137
For research use only. Not for human or drug use.
